Botanix Pharmaceuticals (BOT) H2 2024 earnings summary

Executive summary

• FDA approval for Sofdra (sofpironium) topical gel, 12.45%, was secured in June 2024 for treating primary axillary hyperhidrosis in adults and children 9+ years old.

• Sofdra is the first new chemical entity approved by the FDA for this indication, targeting a US market of 10 million patients.

• Commercial launch preparations are underway, with an early patient experience program in late Q3 CY2024 and broader US launch in Q4 CY2024.

• Three capital raisings totaling A$96 million were completed to fund launch activities and extinguish future milestone/royalty obligations.

Financial highlights

• Comprehensive loss after tax for FY2024 was $13,709,868, compared to $8,917,281 in FY2023.

• Revenue from continuing operations was $601,820, up from $102,934 in FY2023.

• Cash balance at 30 June 2024 was $79,308,130, up from $10,250,395 at 30 June 2023.

• Net cash outflows from operating activities were $8,127,282, improved from $12,074,064 in FY2023.

• Net working capital surplus at year-end was $79,169,230 (FY2023: $12,093,632).

Outlook and guidance

• Directors believe current funds are sufficient for working capital and launch requirements.

• Management is confident in the ability to raise additional funds if needed.

• Focus remains on successful US launch and commercialization of Sofdra.